InTest Corporation reported a 27.2% year-over-year revenue increase, driven by growth in AI and defense/aerospace sectors. The company also showed significant margin expansion and a robust order backlog, reflecting strength across diverse markets. Looking ahead, InTest aims to reach $235 million to $285 million in revenue by 2030, with an organic growth rate of 7-9% and a 20% operating margin, supported by innovation and targeted acquisitions. Key growth areas include advanced packaging and defense/aerospace, which underpin the company's long-term growth strategy.
Cornerstone has released an updated version of the EPA's GHG Emission Factors Hub, providing free, consolidated data for scopes 1, 2, and 3 greenhouse gas emissions. This update includes new factors for air travel, refrigerants, and aligns with the l...
Lyell Immunopharma presented updated safety and translational data for its CAR T-cell therapy, ronde-cel, in treating relapsed or refractory large B-cell lymphoma (LBCL). Over 100 patients treated showed no severe cytokine release syndrome (CRS) and ...
Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...
SpaceX began trading on the stock market at $150 per share, above its IPO price of $135, marking the largest public offering in history and valuing the company at about $1.96 trillion. The shares quickly rose to $165, reflecting strong demand that ex...
Space ETFs fell significantly on the day SpaceX launched its IPO, priced at $135 per share with a $1.77 trillion valuation, raising $75 billion in the largest IPO ever. The sell-off reflects investors rotating out of other space stocks to buy SpaceX ...
